Alpert Tracy E, Morbidini-Gaffney Stefania, Chung Chung T, Bogart Jeffrey A, Hahn Seung S, Hsu Jack, Kellman Robert M
Department of Radiation Oncology, Upstate Medical University, Syracuse, New York 13210, USA.
Cancer J. 2004 Nov-Dec;10(6):335-8. doi: 10.1097/00130404-200411000-00001.
The supraglottic larynx has rich lymphatic drainage, resulting in a high incidence of occult cervical metastases, and the optimal treatment of the clinically uninvolved neck in supraglottic laryngeal cancer remains controversial. Selected retrospective series report a greater than 20% regional failure after treatment by radiotherapy alone, and some investigators recommend routine prophylactic neck dissection. We report on our series of patients who received radiotherapy as sole treatment to the clinically negative neck, either to the bilateral neck for N0 disease or to the contralateral neck for ipsilateral lymphatic involvement.
Between 1971 and 1998, 150 patients with supraglottic laryngeal cancer received radiotherapy alone to the clinically negative neck. Fifty-two patients had ipsilateral lymph node metastases (N1 = 16, N2a = 12, N2b = 20, N3 = 4), and 98 patients had no clinical nodal involvement. The primary site (T1/T2 = 74, T3/T4 = 76) was treated with radiotherapy (N = 91) or laryngectomy plus radiotherapy (N = 59). Neck dissection was performed on the involved neck in 36/52 node-positive patients for either multiple involved nodes (N = 20) or size > 3 cm (N = 16). Radiotherapy was delivered in standard fractionation and field arrangement. The median dose to the clinically negative neck was 5000 cGy (range: 4860-6000 cGy).
With a median follow-up of 48 months, the clinically negative neck was the first site of failure in 3.3% of patients. The contralateral neck remained disease free in all patients. Five failures occurred in the N0 neck, and the median time to recurrence was 12 months (range: 5-30 months). Salvage therapy was neck dissection for the N0 neck failures. The 5-year locoregional control, disease-specific survival, and overall survival were 69%, 74%, and 61%, respectively.
Our data support the use of radiotherapy as a prophylactic treatment for the clinically negative neck. Tumor control in the clinically uninvolved cervical lymphatics is comparable to that in surgical series, suggesting that routine neck dissection may not be necessary. Prospective trials are necessary to further define the role of radiotherapy in this patient population.
声门上喉具有丰富的淋巴引流,导致隐匿性颈部转移的发生率较高,声门上喉癌临床未受累颈部的最佳治疗方法仍存在争议。部分回顾性系列报道显示,单纯放疗后区域失败率超过20%,一些研究者建议进行常规预防性颈部清扫术。我们报告了一系列仅接受放疗作为临床阴性颈部唯一治疗方法的患者,对于N0疾病患者进行双侧颈部放疗,对于同侧淋巴受累患者进行对侧颈部放疗。
1971年至1998年间,150名声门上喉癌患者仅接受临床阴性颈部的放疗。52例患者有同侧淋巴结转移(N1 = 16,N2a = 12,N2b = 20,N3 = 4),98例患者无临床淋巴结受累。原发部位(T1/T2 = 74,T3/T4 = 76)接受放疗(N = 91)或喉切除术加放疗(N = 59)。36/52例淋巴结阳性患者因多个淋巴结受累(N = 20)或大小> 3 cm(N = 16)而对受累颈部进行了颈部清扫术。放疗采用标准分割和野设置。临床阴性颈部的中位剂量为5000 cGy(范围:4860 - 6000 cGy)。
中位随访48个月,3.3%的患者临床阴性颈部是首次失败部位。所有患者的对侧颈部均无疾病。N0颈部出现5例失败,复发的中位时间为12个月(范围:5 - 30个月)。挽救性治疗是对N0颈部失败进行颈部清扫术。5年局部区域控制率、疾病特异性生存率和总生存率分别为69%、74%和61%。
我们的数据支持将放疗作为临床阴性颈部的预防性治疗方法。临床未受累颈部淋巴管的肿瘤控制与手术系列相当,表明可能无需常规颈部清扫术。需要进行前瞻性试验以进一步明确放疗在该患者群体中的作用。